Print Page  |  Close Window

Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
09/04/18Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
STOUGHTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. The following posters will be presented during the poster session on Thursday, September 6th from 6:30 pm - 8:30 pm PT: Poster #39, presented by Dr. Janetta Iwanicki, Scientific Director of Research and Surveillance at Rocky Mountain... 
Printer Friendly Version
08/08/18Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash balance at end of 2018 anticipated to be at least $135.0 million Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2018 and prov... 
Printer Friendly Version
07/20/18Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 126-8317.  An audio web... 
Printer Friendly Version
07/10/18Collegium Announces Promotion of Scott Dreyer to CCO
CANTON, Mass., July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018. Mr. Dreyer brings over 25 years of commercial leadership and expertise, in both biotechnology and pharmaceutical companies. “We’re pleased to promote Scott to serve as our Chief Commercial Officer,” commented Joe Ciaffoni, Collegium’s CEO. “Scott is a prov... 
Printer Friendly Version
06/04/18Collegium Announces CEO Succession
Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that Joseph Ciaffoni, Executive Vice President and Chief Operating Officer at Collegium will be promoted to Chief Executive Officer and join the board of directors effective July 1, 2018. Mr. Ciaffoni will succeed Michael T. Heffernan as Chief Executive Officer. Mr. ... 
Printer Friendly Version
05/30/18Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies Global Healthcare Conference on Thursday, June 7th at 9:30 a.m. ET in New York City The William Blair Growth Stock Conference on Wednesday, June 13th at 9:00 a.m. ET in Chicago About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on becomin... 
Printer Friendly Version
05/09/18Collegium Reports First Quarter Financial Results and Provides Corporate Update
Net revenue of $63.7 million, compared to $10.8 million in Q4 2017  Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2018 and provided a corporate update.  “Our significant growth in the first quar... 
Printer Friendly Version
05/02/18Collegium to Present at the Deutsche Bank Health Care Conference
CANTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for... 
Printer Friendly Version
04/20/18Collegium to Host Conference Call to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass., April 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 799-9797.  An audio webca... 
Printer Friendly Version
04/04/18Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, dif... 
Printer Friendly Version
03/19/18Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
CANTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms. Kuhlmann will oversee all legal and compliance matters for the company. “We are pleased to have Shirley join our leadership team at this exciting time,” said Mike Heffernan, Collegium’s CEO. “Shirley’s previous role at Pepper... 
Printer Friendly Version
03/16/18Collegium to Present at Upcoming Investor Conferences
CANTON, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March: The Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21st at 9:10 a.m. ET in New York City The Needham 17th Annual Healthcare Conference on Wednesday, March 28th at 10:30 a.m. ET in New York City About Collegium Pharmaceutical, Inc. Collegium is a specialty ph... 
Printer Friendly Version
03/07/18Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded product portfolio by licensing rights to commercialize Nucynta franchise Revenue growth and strong balance sheet provide cash runway into 2020 Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the fourth quar... 
Printer Friendly Version
02/26/18Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update. Conference Call Information:  To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 764-8078.  An audio webc... 
Printer Friendly Version
01/10/18Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing commercial infrastructure CANTON, Mass., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has closed the transactions contemplated by its commercialization agreement (the “Agreement”) with Depomed, Inc. (“Depomed”) pu... 
Printer Friendly Version